Representative changes in CRP, hemoglobin, and IgG concentrations in a patient with multicentric Castleman's disease during treatment with anit-IL-6R (rhPM-1).

Arrows and shadings indicate the administration of rhPM-1. Note that treatment with rhPM-1 improved the clinical abnormalities, but that these recurred 2 weeks after the cessation of the rhPM-1 regimen. Readministration of rhPM-1 was as effective as the first treatment.